OBJECTIVES: Health policy chances may effect the conducted studies in all fields. Pharmacoeconomics dossiers for the reimbursement applications for new medicines were not mandatory before year 2008. New molecules need to show cost-effectiveness and possible budget effect with their applications for reimbursement to Social Security Institution from 2008. This policy changing may effect pharmacoeconomics and health outcome studies in Turkey. The aim of the study is to evaluate the improvement of pharmacoeconomics and health outcome studies which are specific for Turkey in years. METHODS: Database of ISPOR Outcome Research Digest were searched online from  the begining of database (1998) to 2011 with the key words “Turkey” and “Turkish”. The inclusion criteria were taken as study must be specific for Turkey and first author must be from Turkey. Included abstract evaluated for increasing in years, distribution in study topics and diseases areas. RESULTS: 121 abstracts were matched with inclusion criteria. First abstracts were published in 2000. There were only 16 abstracts in total until 2008. After year 2008, published abstracts numbers were increased year by year and reached up to 40 per year in 2012. 58.7% of all abstracts were Cost Studies(CS). It was followed by Health Care Use & Policy Studies(HP) (15.7%) and Patient Reported Outcomes & Preference-Based Studies (PRO) (12,7%). 49.3% of all Cost Studies were Cost-Effectiveness studies. 17.4% of all abstracts were in the Alergy diseases area. It was followed by Multiple Diseases (14%). CONCLUSIONS: It was shown that the policy changing in 2008 as to require pharmacoeconomics dossiers  in the reimbursement application effected Turkey specific pharmacoeconomic and health outcome studies positively. In other words, pharmaceutical ýndustry and the government started to invest in pharmacoeconomics and health outcome studies after 2008.